While Punxsutawney Phil gets most of the headlines, there are well over a dozen other groundhogs nationwide that clock in on ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

One person was taken to the hospital after a house caught fire in. Firefighters were called to the 1600 block of Cambridge ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...